3 Cash-Heavy Stocks to Target This Week

Barchart·06/16/2026 04:10:04

A clean balance sheet can signal disciplined management and stability. It also means a company can expand and thrive without relying on borrowed capital.

Finding the best investments isn’t always easy, and that’s why we started StockStory. Keeping that in mind, here are three companies with net cash positions that can continue growing sustainably.

Vita Coco (COCO)

Net Cash Position: $189 million (4.2% of Market Cap)

Founded in 2004 followed by a 2021 IPO, The Vita Coco Company (NASDAQ:COCO) offers coconut water products that are a natural way to quench thirst.

Why Will COCO Outperform?

1. Products are selling at a rapid clip as its unit sales averaged an outstanding 13.8% growth rate over the past two years
2. Earnings growth has massively outpaced its peers over the last three years as its EPS has compounded at 52.4% annually
3. Market-beating returns on capital illustrate that management has a knack for investing in profitable ventures, and its returns are climbing as it finds even more attractive growth opportunities

Vita Coco’s stock price of $82.81 implies a valuation ratio of 44.5x forward P/E. Is now a good time to buy? Find out in our full research report, it’s free.

Brady (BRC)

Net Cash Position: $86.98 million (2.3% of Market Cap)

Founded in 1914 and evolving through more than a century of industrial innovation, Brady (NYSE:BRC) manufactures and supplies identification solutions and workplace safety products that help companies identify and protect their premises, products, and people.

Why Do We Love BRC?

1. Annual revenue growth of 9.9% over the past two years was outstanding, reflecting market share gains this cycle
2. Projected revenue growth of 30% for the next 12 months is above its two-year trend, pointing to accelerating demand
3. Performance over the past five years was turbocharged by share buybacks, which enabled its earnings per share to grow faster than its revenue

At $84.58 per share, Brady trades at 14.2x forward P/E. Is now the right time to buy? See for yourself in our full research report, it’s free.

Globus Medical (GMED)

Net Cash Position: $529.5 million (4.8% of Market Cap)

With operations spanning 64 countries and a portfolio of over 10 new products launched in 2023 alone, Globus Medical (NYSE:GMED) develops and sells implantable devices, surgical instruments, and technology solutions for spine, orthopedic, and neurosurgical procedures.

Why Does GMED Stand Out?

1. Market share has increased this cycle as its 30.3% annual revenue growth over the last five years was exceptional
2. Average constant currency growth of 22.8% over the past two years demonstrates its ability to grow internationally despite currency fluctuations
3. Earnings per share grew by 22.2% annually over the last five years and trumped its peers

Globus Medical is trading at $78.50 per share, or 16.7x forward P/E. Is now the time to initiate a position? Find out in our full research report, it’s free.

High-Quality Stocks for All Market Conditions

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.